Id1 and Id3 co-expression correlates with clinical outcome in stage III-N2 non-small cell lung cancer patients treated with definitive chemoradiotherapy

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Castañon, Eduardo ^a   Bosch Barrera, Joaquim ^a   López, Inés ^b   Collado, Víctor ^b   Moreno, Marta ^a   López Picazo, José María ^a   Arbea, Leire ^a   Lozano, María Dolores ^a   Calvo, Alfonso ^b   Gil Bazo, Ignacio ^a,b  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Non small cell lung cancerChemoradiotherapyId1Id3Protein expression; Prognosis

Indexed keywords

CISPLATIN; INHIBITOR OF DIFFERENTIATION 1; INHIBITOR OF DIFFERENTIATION 3; MONOCLONAL ANTIBODY; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CARCINOGENESIS; CHEMORADIOTHERAPY; CLINICAL ARTICLE; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MALE; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; SQUAMOUS CELL CARCINOMA; TREATMENT RESPONSE;

ADULT; AGED; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITOR OF DIFFERENTIATION PROTEIN 1; INHIBITOR OF DIFFERENTIATION PROTEINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; TREATMENT OUTCOME;

EID: 84873656565     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-13     Document Type: Article

References (28)

1. Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Rami-Porta R, et al. The IASLC lung cancer staging project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM classification of malignant tumours. J Thorac Oncol 2007, 2:706-714. 10.1097/JTO.0b013e31812f3c1a, 17762336.
2. Stinchcombe TE, Lee CB, Moore DT, Rivera MP, Halle J, Limentani S, et al. Long-term follow-up of a phase I/II trial of dose escalating three-dimensional conformal thoracic radiation therapy with induction and concurrent carboplatin and paclitaxel in unresectable stage IIIA/B non-small cell lung cancer. J Thorac Oncol 2008, 3:1279-1285. 10.1097/JTO.0b013e31818b1971, 18978563.
3. Stinchcombe TE, Hodgson L, Herndon JE, Kelley MJ, Cicchetti MG, Ramnath N, et al. Treatment outcomes of different prognostic groups of patients on cancer and leukemia group B trial 39801: induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for unresectable stage III non-small cell lung cancer. J Thorac Oncol 2009, 4:1117-1125. 10.1097/JTO.0b013e3181b27b33, 2778485, 19652624.
4. Bosch-Barrera J, Garcia-Franco C, Guillen-Grima F, Moreno-Jimenez M, Lopez-Picazo JM, Gurpide A, et al. The multimodal management of locally advanced N2 non-small cell lung cancer: is there a role for surgical resection? A single institution's experience. Clin Transl Oncol 2012, 14:835-841. 10.1007/s12094-012-0874-3, 22855163.
5. Coate LE, John T, Tsao MS, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. Lancet Oncol 2009, 10:1001-1010. 10.1016/S1470-2045(09)70155-X, 19796752.
6. Benezra R, Davis RL, Lockshon D, Turner DL, Weintraub H. The protein Id: a negative regulator of helix-loop-helix DNA binding proteins. Cell 1990, 61:49-59. 10.1016/0092-8674(90)90214-Y, 2156629.
7. Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R, et al. Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 1999, 401:670-677. 10.1038/44334, 10537105.
8. Perk J, Iavarone A, Benezra R. Id family of helix-loop-helix proteins in cancer. Nat Rev Cancer 2005, 5:603-614. 10.1038/nrc1673, 16034366.
9. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. Modulation of mitogen-activated protein kinase cascades by differentiation-1 protein: acquired drug resistance of hormone independent prostate cancer cells. J Urol 2005, 174:2022-2026. 10.1097/01.ju.0000176476.14572.39, 16217386.
10. Lin JC, Chang SY, Hsieh DS, Lee CF, Yu DS. The association of Id-1, MIF and GSTpi with acquired drug resistance in hormone independent prostate cancer cells. Oncol Rep 2005, 13:983-988.
11. Kamalian L, Gosney JR, Forootan SS, Foster CS, Bao ZZ, Beesley C, et al. Increased expression of Id family proteins in small cell lung cancer and its prognostic significance. Clin Cancer Res 2008, 14:2318-2325. 10.1158/1078-0432.CCR-07-4716, 18413820.
12. Ponz-Sarvise M, Nguewa PA, Pajares MJ, Agorreta J, Lozano MD, Redrado M, et al. Inhibitor of differentiation-1 as a novel prognostic factor in NSCLC patients with adenocarcinoma histology and its potential contribution to therapy resistance. Clin Cancer Res 2011, 17:4155-4166. 10.1158/1078-0432.CCR-10-3381, 21540238.
13. Diaz R, Nguewa PA, Diaz-Gonzalez JA, Hamel E, Gonzalez-Moreno O, Catena R, et al. The novel Akt inhibitor Palomid 529 (P529) enhances the effect of radiotherapy in prostate cancer. Br J Cancer 2009, 100:932-940. 10.1038/sj.bjc.6604938, 2661786,2661786, 19240717.
14. Tsuchiya T, Okaji Y, Tsuno NH, Sakurai D, Tsuchiya N, Kawai K, et al. Targeting Id1 and Id3 inhibits peritoneal metastasis of gastric cancer. Cancer Sci 2005, 96:784-790. 10.1111/j.1349-7006.2005.00113.x, 16271072.
15. Perk J, Gil-Bazo I, Chin Y, de Candia P, Chen JJ, Zhao Y, et al. Reassessment of id1 protein expression in human mammary, prostate, and bladder cancers using a monospecific rabbit monoclonal anti-id1 antibody. Cancer Res 2006, 66:10870-10877. 10.1158/0008-5472.CAN-06-2643, 17108123.
16. Jorda M, Gomez-Fernandez C, Garcia M, Mousavi F, Walker G, Mejias A, et al. P63 differentiates subtypes of nonsmall cell carcinomas of lung in cytologic samples: implications in treatment selection. Cancer 2009, 117:46-50.
17. Rothschild SI, Kappeler A, Ratschiller D, Betticher DC, Tschan MP, Gugger M, et al. The stem cell gene " inhibitor of differentiation 1" (ID1) is frequently expressed in non-small cell lung cancer. Lung Cancer 2011, 71:306-311. 10.1016/j.lungcan.2010.06.018, 20709421.
18. Poomthavorn P, Wong SH, Higgins S, Werther GA, Russo VC. Activation of a prometastatic gene expression program in hypoxic neuroblastoma cells. Endocr Relat Cancer 2009, 16:991-1004. 10.1677/ERC-08-0340, 19423615.
19. Lofstedt T, Jogi A, Sigvardsson M, Gradin K, Poellinger L, Pahlman S, et al. Induction of ID2 expression by hypoxia-inducible factor-1: a role in dedifferentiation of hypoxic neuroblastoma cells. J Biol Chem 2004, 279:39223-39231. 10.1074/jbc.M402904200, 15252039.
20. Bollineni VR, Wiegman EM, Pruim J, Groen HJ, Langendijk JA. Hypoxia imaging using positron emission tomography in non-small cell lung cancer: implications for radiotherapy. Cancer Treat Rev 2012, 31:1027-1032.
21. Choi N, Baumann M, Flentjie M, Kellokumpu-Lehtinen P, Senan S, Zamboglou N, et al. Predictive factors in radiotherapy for non-small cell lung cancer: present status. Lung Cancer 2001, 31:43-56. 10.1016/S0169-5002(00)00156-2, 11162866.
22. Mern DS, Hoppe-Seyler K, Hoppe-Seyler F, Hasskarl J, Burwinkel B. Targeting Id1 and Id3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest, and apoptosis in breast cancer cells. Breast Cancer Res Treat 2010, 124:623-633. 10.1007/s10549-010-0810-6, 20191379.
23. Shuno Y, Tsuno NH, Okaji Y, Tsuchiya T, Sakurai D, Nishikawa T, et al. Id1/Id3 knockdown inhibits metastatic potential of pancreatic cancer. J Surg Res 2010, 161:76-82. 10.1016/j.jss.2008.10.031, 19515385.
24. Gupta GP, Perk J, Acharyya S, de Candia P, Mittal V, Todorova-Manova K, et al. ID genes mediate tumor reinitiation during breast cancer lung metastasis. Proc Natl Acad Sci U S A 2007, 104:19506-19511. 10.1073/pnas.0709185104, 2148319, 18048329.
25. O'Brien CA, Kreso A, Ryan P, Hermans KG, Gibson L, Wang Y, et al. ID1 and ID3 regulate the self-renewal capacity of human colon cancer-initiating cells through p21. Cancer Cell 2012, 21:777-792. 10.1016/j.ccr.2012.04.036, 22698403.
26. Perry SS, Zhao Y, Nie L, Cochrane SW, Huang Z, Sun XH. Id1, but not Id3, directs long-term repopulating hematopoietic stem-cell maintenance. Blood 2007, 110:2351-2360. 10.1182/blood-2007-01-069914, 1988946, 17622570.
27. Chaudhary J, Johnson J, Kim G, Skinner MK. Hormonal regulation and differential actions of the helix-loop-helix transcriptional inhibitors of differentiation (Id1, Id2, Id3, and Id4) in Sertoli cells. Endocrinology 2001, 142:1727-1736. 10.1210/en.142.5.1727, 11316735.
28. Kimbrell HZ, Gustafson KS, Huang M, Ehya H. Subclassification of non-small cell lung cancer by cytologic sampling: a logical approach with selective use of immunocytochemistry. Acta Cytol 2012, 56:419-424. 10.1159/000338519, 22846197.